A synthetic DNA industry leader warned that biosecurity screening remains too dependent on voluntary compliance and called for national standards and enforcement. In a commentary, the author argued that current provider screening—while helpful—operates largely as an honor system and can be undermined by a single noncompliant vendor. The piece emphasized how screening works in practice (checking sequences tied to pathogens or toxins and investigating customers and intended use) while citing operational costs and delays as part of responsible provision. The risk profile is escalating as AI tools enable longer, more complex genetic designs that may reduce the effectiveness of database-driven comparisons against known threats. The intervention frames biosecurity as a collective infrastructure issue that requires oversight, consistent rules, and consequences for failures, particularly as sequence design capabilities accelerate drug development and engineered biology.